Nedisertib

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameNedisertib
Drug Alias NamePeposertibM-3814MSC-2490484A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA-dependent protein kinase inhibitors
TargetsDNA-dependent protein kinase
Therapy Area/IndicationsBone metastasesGastroenteropancreatic neuroendocrine tumorSolid tumours +[35] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesEmd Serono Research & Development Institute IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany
Active IndicationsBone metastasesGastroenteropancreatic neuroendocrine tumorSolid tumours +[33] 
Inactive IndicationsSmall Cell Lung CarcinomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A